JENNIFER WARGO to Imidazoles
This is a "connection" page, showing publications JENNIFER WARGO has written about Imidazoles.
Connection Strength
0.655
-
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
Score: 0.392
-
Interaction of molecular alterations with immune response in melanoma. Cancer. 2017 06 01; 123(S11):2130-2142.
Score: 0.094
-
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31.
Score: 0.069
-
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
Score: 0.022
-
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest. 2015 Apr; 125(4):1459-70.
Score: 0.020
-
Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 2014 Nov 01; 193(9):4722-31.
Score: 0.019
-
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014; 9(7):e101286.
Score: 0.019
-
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014 Jan; 4(1):61-8.
Score: 0.018